MarkerTest Distribution offers an unique investment opportunity fueled by Expert Knowledge, Partners with State of the Art Equipment and Advanced Testing Procedures that provide a winning value proposition for Urine Drug Testing (UDT) capability in the explosive multi-billion niche market of Chronic Pain Medication Testing in the United States.
Another major competitive advantage for MarkerTest Distribution is UR Code, a soft gel capsule or liquid ingested by the patient that not only provides identification codes in the patients urine, making substitution, dilution, and adulteration virtually impossible without detection but also eliminates costly and invasive sample observation.
UR Code is the only urine drug test that consistently provides client with accurate and reliable results - effectively eliminating the rising economic and social costs of the up to 20 percent of tests deliberately falsified in urine testing.
MarkerTest Distribution is seeking private investment funds to advance the distribution network of UR Code throughout the USA, Canada and Mexico.
If you are an Accredited Investor and have an interest in investing in MarkerTest Distribution please fill out the information below and we will send you investment information.